Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$5.41
-2.9%
$4.76
$3.42
$7.20
$304.12M1.941.52 million shs571,861 shs
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$8.09
+1.3%
$7.95
$5.15
$10.67
$1.09B1.161.33 million shs1.04 million shs
CureVac stock logo
CVAC
CureVac
$4.46
+0.5%
$3.52
$2.37
$5.28
$1.00B2.49721,815 shs437,407 shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$15.62
+0.6%
$14.43
$8.24
$18.38
$1.02B-0.3500,775 shs415,796 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-2.87%-1.99%+17.35%+13.66%-11.17%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
+1.25%+1.25%-0.55%-0.74%+48.17%
CureVac stock logo
CVAC
CureVac
+0.45%-3.67%+32.74%+46.71%-1.55%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
+0.64%-0.26%+8.02%+48.48%+15.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.6262 of 5 stars
0.02.00.00.03.00.80.6
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.049 of 5 stars
3.52.00.00.02.71.71.9
CureVac stock logo
CVAC
CureVac
4.0259 of 5 stars
3.52.00.04.82.70.01.3
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.4383 of 5 stars
3.51.00.00.01.95.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5042.15% Upside
CureVac stock logo
CVAC
CureVac
3.00
Buy$11.00146.64% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
3.00
Buy$38.00143.28% Upside

Current Analyst Ratings Breakdown

Latest ACB, AUPH, CVAC, and MLYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
CureVac stock logo
CVAC
CureVac
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$10.00
5/14/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$48.00
5/13/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/30/2025
CureVac stock logo
CVAC
CureVac
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
4/2/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$30.00 ➝ $42.00
3/10/2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M0.95$0.21 per share26.35$8.18 per share0.66
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$247.30M4.42N/AN/A$2.63 per share3.08
CureVac stock logo
CVAC
CureVac
$523.70M1.91N/AN/A$2.50 per share1.78
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$3.84 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05108.2212.30N/A0.42%0.59%0.42%6/18/2025 (Estimated)
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
-$78.02M$0.28N/A14.45N/A-10.23%-4.41%-3.07%7/30/2025 (Estimated)
CureVac stock logo
CVAC
CureVac
-$281.58M$0.928.11N/AN/A20.72%21.98%15.72%8/13/2025 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)

Latest ACB, AUPH, CVAC, and MLYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11N/AN/AN/A$88.85 millionN/A
5/22/2025Q1 2025
CureVac stock logo
CVAC
CureVac
-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/12/2025Q1 2025
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$1.02-$0.79+$0.23-$0.79N/AN/A
4/10/2025Q4 2024
CureVac stock logo
CVAC
CureVac
-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
CureVac stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
0.17
5.60
5.11
CureVac stock logo
CVAC
CureVac
0.05
6.20
6.19
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/A
14.02
14.02

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
CureVac stock logo
CVAC
CureVac
17.26%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
CureVac stock logo
CVAC
CureVac
2.15%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
25.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Aurinia Pharmaceuticals Inc. stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million137.02 millionOptionable
CureVac stock logo
CVAC
CureVac
880224.34 million219.07 millionOptionable
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2865.18 million33.27 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$5.41 -0.16 (-2.87%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$5.32 -0.09 (-1.66%)
As of 06/5/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.09 +0.10 (+1.25%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$8.07 -0.02 (-0.19%)
As of 06/5/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

CureVac stock logo

CureVac NASDAQ:CVAC

$4.46 +0.02 (+0.45%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$4.52 +0.06 (+1.43%)
As of 06/5/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$15.62 +0.10 (+0.64%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$15.62 0.00 (0.00%)
As of 06/5/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.